Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders.
The last earnings update was 162 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Synergy Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Synergy Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Synergy Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Synergy Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
Synergy Pharmaceuticals has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
Take a look at our analysis of S90’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Synergy Pharmaceuticals's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Synergy Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Synergy Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Synergy Pharmaceuticals's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Synergy Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Synergy Pharmaceuticals is high growth as no earnings estimate data is available.
Unable to determine if Synergy Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Synergy Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Synergy Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Synergy Pharmaceuticals's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Synergy Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Synergy Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Synergy Pharmaceuticals has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Troy Hamilton, PharmD, M.B.A. has been Chief Executive Officer of Synergy Pharmaceuticals, Inc. since December 19, 2017 and has been its Director since January 19, 2018. Mr. Hamilton served as the Chief Commercial Officer of Synergy Pharmaceuticals, Inc., from July 2015 to December 2017 and its Executive Vice President from February 2016 to December 2017. He served as Senior Vice President of Synergy Pharmaceuticals, Inc. from July 2015 to February 2016. Mr. Hamilton has over 21 years of experience in the pharmaceutical industry, with an emphasis on general management, P&L responsibility, commercialization, partnerships, acquisitions and global product launches in the gastroenterology and primary care markets. Prior to joining Synergy, he held multiple commercial leadership roles over a nine year period within Shire Pharmaceuticals' GI Business Unit. Most recently, he served as Vice President of Product Strategy and Commercial Lead for Shire’s Gastrointestinal (GI) Business Unit, responsible for the GI motility, hepatology and pipeline products. In this role, Mr. Hamilton also led the GI business development efforts and was involved in all of their recent GI-related company acquisitions. Prior to this, he served as Vice President of GI International Marketing as part of a two year international assignment based in Belgium and as General Manager for the Inflammatory Bowel Disease franchise globally. He joined Shire in 2006 as the Head of US Marketing, leading the successful launch of Lialda and continued commercialization of Pentasa. Previously, Mr. Hamilton spent 10 years at Johnson & Johnson's Janssen Pharmaceuticals and McNeil Specialty Products in a number of in-house and field-based leadership roles within GI/primary careÂ brand management, strategic planning, new product development and medical services. Mr. Hamilton holds a BSc in Pharmacy and PharmD from the University of the Sciences in Philadelphia and an MBA from St. Joseph University.
Troy's compensation has increased whilst company is loss making.
Troy's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Synergy Pharmaceuticals management team is less than 2 years, this suggests a new team.
CEO & Director
Executive VP & CFO
Vice President of Investor Relations and Corporate Communications
Senior Vice President of Marketing
Senior VP of Sales & Market Access
Senior Vice President of Drug Development
Interim Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Synergy Pharmaceuticals board of directors is about average.
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.